Choroidal Thickness in Glaucoma Patients and Healthy Controls
NCT ID: NCT01293474
Last Updated: 2015-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2011-02-28
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Trial with medical device
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
NCT02622191
The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal Micro-structure
NCT02807935
The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes
NCT01067482
Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure
NCT01333891
Efficacy of Selective Laser Trabeculoplasty in Pseudophakic Patients
NCT01467388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
glaucoma patients
patients with diagnosis of primary open angle glaucoma
Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the choroidal thickness with Spectralis® SD-OCT
control group
age matched healthy controls
Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the choroidal thickness with Spectralis® SD-OCT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the choroidal thickness with Spectralis® SD-OCT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
for the glaucoma study group: diagnosis of primary open angle glaucoma (POAG)
Exclusion Criteria
* any pathology of the central retina
* any optic nerve disorder other then glaucoma
* retinal vascular disorder
for the glaucoma study group: other glaucoma diagnosis then primary open angle glaucoma
for the control group: any diagnosis of glaucoma
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Kniestedt, Ass. Prof., MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Ophtalmic Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich, Ophthalmic Clinic
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EDI-OCT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.